Obesity drugs – potential $100 billion for monopolists

As the buzz around injectable weight-loss drugs grows louder, Goldman Sachs Group analysts predict the new market will reach $100 billion, with Eli Lilly and Novo Nordisk leading the way, according to Bloomberg.

Eli Lilly, whose drug roster includes the injectable diabetes and obesity drug tirzepatide, is now the world’s largest health care company by market value.

Meanwhile, Novo Nordisk became Europe’s most profitable listed company last month, boosted by market enthusiasm for the obesity and diabetes drug semaglutide (Ozempic). Shares of both companies have risen this year..

“The chronic obesity market is at an inflection point,” wrote analysts including Chris Shibutani. They see future opportunities for “sustained growth and cutting-edge capabilities that we estimate could ultimately lead to some of the most profitable drugs of all time.”

https://rua.gr/wom/healt/56831-pokhudenie-molochnyj-chaj-kak-sredstvo-dlya-utoleniya-goloda.html
Goldman analysts predict that The global anti-obesity drug market will grow to about $100 billion in 2030, up from annual sales of about $6 billion earlier this year. This is based on the fact that approximately 15 million adults in the US are treated with anti-obesity drugs out of an estimated 105 million adultswho are obese or overweight. Analysts have excluded diabetics from their obesity forecasts.

Novo Nordisk’s weight loss and diabetes drugs, a class of drugs known as GLP-1 blockers, share the same active ingredient semaglutide. They They work by suppressing appetite, as well as slowing down the movement of food through the digestive system (a person does not feel hungry and, accordingly, eats much less).

Meanwhile, Lilly’s tirezepatide, already approved to treat diabetes, is expected to hit the market by the end of the year. Lilly and Novo Nordisk will have a monopoly, with the two pharmaceutical companies capturing about 80% of the obesity market by 2030, according to Goldman analysts.

Source link